Cargando…
VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy
V-domain immunoglobulin suppressor of T cell activation (VISTA) is a novel negative checkpoint receptor (NCR) primarily involved in maintaining immune tolerance. It has a role in the pathogenesis of autoimmune disorders and cancer and has shown promising results as a therapeutic target. However, the...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631023/ https://www.ncbi.nlm.nih.gov/pubmed/37936192 http://dx.doi.org/10.1186/s12935-023-03116-0 |
_version_ | 1785132279712972800 |
---|---|
author | Shekari, Najibeh Shanehbandi, Dariush Kazemi, Tohid Zarredar, Habib Baradaran, Behzad Jalali, Seyed Amir |
author_facet | Shekari, Najibeh Shanehbandi, Dariush Kazemi, Tohid Zarredar, Habib Baradaran, Behzad Jalali, Seyed Amir |
author_sort | Shekari, Najibeh |
collection | PubMed |
description | V-domain immunoglobulin suppressor of T cell activation (VISTA) is a novel negative checkpoint receptor (NCR) primarily involved in maintaining immune tolerance. It has a role in the pathogenesis of autoimmune disorders and cancer and has shown promising results as a therapeutic target. However, there is still some ambiguity regarding the ligands of VISTA and their interactions with each other. While V-Set and Immunoglobulin domain containing 3 (VSIG-3) and P-selectin glycoprotein ligand-1(PSGL-1) have been extensively studied as ligands for VISTA, the others have received less attention. It seems that investigating VISTA ligands, reviewing their functions and roles, as well as outcomes related to their interactions, may allow an understanding of their full functionality and effects within the cell or the microenvironment. It could also help discover alternative approaches to target the VISTA pathway without causing related side effects. In this regard, we summarize current evidence about VISTA, its related ligands, their interactions and effects, as well as their preclinical and clinical targeting agents. |
format | Online Article Text |
id | pubmed-10631023 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106310232023-11-07 VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy Shekari, Najibeh Shanehbandi, Dariush Kazemi, Tohid Zarredar, Habib Baradaran, Behzad Jalali, Seyed Amir Cancer Cell Int Review V-domain immunoglobulin suppressor of T cell activation (VISTA) is a novel negative checkpoint receptor (NCR) primarily involved in maintaining immune tolerance. It has a role in the pathogenesis of autoimmune disorders and cancer and has shown promising results as a therapeutic target. However, there is still some ambiguity regarding the ligands of VISTA and their interactions with each other. While V-Set and Immunoglobulin domain containing 3 (VSIG-3) and P-selectin glycoprotein ligand-1(PSGL-1) have been extensively studied as ligands for VISTA, the others have received less attention. It seems that investigating VISTA ligands, reviewing their functions and roles, as well as outcomes related to their interactions, may allow an understanding of their full functionality and effects within the cell or the microenvironment. It could also help discover alternative approaches to target the VISTA pathway without causing related side effects. In this regard, we summarize current evidence about VISTA, its related ligands, their interactions and effects, as well as their preclinical and clinical targeting agents. BioMed Central 2023-11-07 /pmc/articles/PMC10631023/ /pubmed/37936192 http://dx.doi.org/10.1186/s12935-023-03116-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Shekari, Najibeh Shanehbandi, Dariush Kazemi, Tohid Zarredar, Habib Baradaran, Behzad Jalali, Seyed Amir VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy |
title | VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy |
title_full | VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy |
title_fullStr | VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy |
title_full_unstemmed | VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy |
title_short | VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy |
title_sort | vista and its ligands: the next generation of promising therapeutic targets in immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631023/ https://www.ncbi.nlm.nih.gov/pubmed/37936192 http://dx.doi.org/10.1186/s12935-023-03116-0 |
work_keys_str_mv | AT shekarinajibeh vistaanditsligandsthenextgenerationofpromisingtherapeutictargetsinimmunotherapy AT shanehbandidariush vistaanditsligandsthenextgenerationofpromisingtherapeutictargetsinimmunotherapy AT kazemitohid vistaanditsligandsthenextgenerationofpromisingtherapeutictargetsinimmunotherapy AT zarredarhabib vistaanditsligandsthenextgenerationofpromisingtherapeutictargetsinimmunotherapy AT baradaranbehzad vistaanditsligandsthenextgenerationofpromisingtherapeutictargetsinimmunotherapy AT jalaliseyedamir vistaanditsligandsthenextgenerationofpromisingtherapeutictargetsinimmunotherapy |